Beneficial Effects of HIV Peptidase Inhibitors on Fonsecaea pedrosoi: Promising Compounds to Arrest Key Fungal Biological Processes and Virulence
Open Access
- 13 October 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (10) , e3382
Abstract
Fonsecaea pedrosoi is the principal etiologic agent of chromoblastomycosis, a fungal disease whose pathogenic events are poorly understood. Current therapy for chromoblastomycosis is suboptimal due to toxicity of the available therapeutic agents and the emergence of drug resistance. Compounding these problems is the fact that endemic countries and regions are economically poor. In the present work, we have investigated the effect of human immunodeficiency virus (HIV) peptidase inhibitors (PIs) on the F. pedrosoi conidial secreted peptidase, growth, ultrastructure and interaction with different mammalian cells. All the PIs impaired the acidic conidial-derived peptidase activity in a dose-dependent fashion, in which nelfinavir produced the best inhibitory effect. F. pedrosoi growth was also significantly reduced upon exposure to PIs, especially nelfinavir and saquinavir. PIs treatment caused profound changes in the conidial ultrastructure as shown by transmission electron microscopy, including invaginations in the cytoplasmic membrane, disorder and detachment of the cell wall, enlargement of fungi cytoplasmic vacuoles, and abnormal cell division. The synergistic action on growth ability between nelfinavir and amphotericin B, when both were used at sub-inhibitory concentrations, was also observed. PIs reduced the adhesion and endocytic indexes during the interaction between conidia and epithelial cells (CHO), fibroblasts or macrophages, in a cell type-dependent manner. Moreover, PIs interfered with the conidia into mycelia transformation when in contact with CHO and with the susceptibility killing by macrophage cells. Overall, by providing the first evidence that HIV PIs directly affects F. pedrosoi development and virulence, these data add new insights on the wide-spectrum efficacy of HIV PIs, further arguing for the potential chemotherapeutic targets for aspartyl-type peptidase produced by this human pathogen.Keywords
This publication has 51 references indexed in Scilit:
- The major chromoblastomycosis fungal pathogen,Fonsecaea pedrosoi, extracellularly releases proteolytic enzymes whose expression is modulated by culture medium composition: implications on the fungal development and cleavage of key's host structuresFEMS Immunology & Medical Microbiology, 2006
- Antileishmanial activity of HIV protease inhibitorsInternational Journal of Antimicrobial Agents, 2005
- Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strainsPharmacological Research, 2004
- The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogenCryptococcus neoformansFEMS Immunology & Medical Microbiology, 2004
- Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agentsMycoses, 2004
- Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimensJournal of Antimicrobial Chemotherapy, 2003
- Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of bothInternational Journal of Dermatology, 1997
- The in vitro susceptibility ofFonsecaea pedrosoi to activated macrophagesMycopathologia, 1994
- Modulation of Experimental Systemic Murine Candidosis by Intravenous PepstatinZentralblatt für Bakteriologie, 1990
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970